Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial

Abstract Background Anthracycline-containing neoadjuvant chemotherapy (NACT) is the standard treatment for early triple-negative breast cancer (eTNBC); however, it is associated with substantial toxicity. We performed whole transcriptome profiling of baseline tumor biopsies to identify gene networks...

Full description

Saved in:

Bibliographic Details
Main Authors:	Darren Korbie, Clare Stirzaker, Oleg Gluz, Christine zu Eulenburg, Ulrike Nitz, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Rachel Wuerstlein, Enrico Pelz, Hans Heinrich Kreipe, Susan J. Clark, Matt Trau, Monika Graeser, Nadia Harbeck
Format:	Article
Language:	English
Published:	BMC 2025-03-01
Series:	Molecular Cancer
Subjects:	Neoadjuvant therapy Triple negative breast neoplasms Translational research Biomedical Gene regulatory networks Gene expression profiling
Online Access:	https://doi.org/10.1186/s12943-025-02275-0
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial

Similar Items